Hinge Bio

Drug Discovery · Burlingame, CA · Founded 2015 · Privately Held (backing)

Operator of a biotech company intended to work for the development of a new class of flexible, extendible, and cooperatively binding therapeutics and diagnostics. Hinge Bio is based in Burlingame, CA and was founded in 2015. It was valued at $46 million at its later-stage round in Jan 2025, the last priced event on record. It has raised $66.8 million across 4 recorded rounds; the latest was a $30.6 million early-stage round in Dec 2024.

PMV mark · valuation
$46.0M
Oct 2026
Priced at
its later-stage round
Jan 2025
Total raised
$66.8M
Last round
Early Stage VC
Dec 2024
What is Hinge Bio worth?
$46.0MPrivateMarketView mark · Oct 2026

Valued at $46.0M at its later-stage round, Jan 2025. Nothing has traded since.

Free account
More of Hinge Bio with a free account
  • ·The complete investor list: 13 names
  • ·Watch Hinge Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Hinge Bio funding history

4 rounds
DateRoundRaisedPost-money
Dec 2024Early Stage VC$30.6M▮
Dec 2020Debt$18.0M▮
Feb 2020Early Stage VC$18.2M▮
Apr 2017Accelerator/Incubator—▮
Unlock post-money valuations

Membership and data by Private Market View

Hinge Bio valuation

Hinge Bio was valued at $46 million at its later-stage round in Jan 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Hinge Bio raised?

Hinge Bio has raised $66.8 million across 4 recorded rounds since 2017. The largest was a $30.6 million early-stage round in Dec 2024.

Hinge Bio has filed 6 Form Ds with the SEC since 2020, most recently in Jan 2025 ($30.6 million sold to 82 investors).

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: ParcelBio ($41.2 million), Persephone Biosciences ($37.3 million) and Solarea Bio ($37 million).

How Hinge Bio's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Hinge Bio, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Hinge Bio

What is Hinge Bio worth?
Hinge Bio is valued at $46.0M as of Oct 2026. Valued at $46.0M at its later-stage round, Jan 2025. Nothing has traded since.
How much has Hinge Bio raised?
Hinge Bio has raised $66.8M in total funding across 4 recorded rounds.
When did Hinge Bio last raise?
Hinge Bio last raised in Dec 2024 (Early Stage VC), raising $30.6M.